Program
Anti-IGSF8 Monoclonal Antibody GV20-0251
Its studies are mostly in Neoplasms · Uterine Cervical Neoplasms, led by GV20 Therapeutics.
Drug pageAnti-IGSF8 Monoclonal Antibody GV20-0251: every studyAll 6 studies of it, academic ones too, with its approvals, label and forms.Furthest: phase 2, since Dec 12, 20223 company-led studies, 3 open or runningNext primary completion: Dec 15, 2026 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GV20 Therapeutics | 33 open or running | phase 2since Dec 12, 2022 | Dec 12, 2022 | Dec 15, 2026phase 2 · NCT05669430 |
Also a collaborator on its studies: Merck.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 12, 2022First study: phase 2 study in NeoplasmsFirst studyNCT05669430 · 365 planned · United States
- Jun 26, 2025Phase 2 study in NeoplasmsNCT07070518 · 350 planned · China
- May 29, 2026Phase 2 study in Uterine Cervical NeoplasmsNCT07623642 · 227 planned · China
Ahead
- Dec 15, 2026Primary completion: phase 2 study in NeoplasmsNCT05669430
- Jul 16, 2027Primary completion: phase 2 study in NeoplasmsNCT07070518
- Jun 15, 2028Primary completion: phase 2 study in Uterine Cervical NeoplasmsNCT07623642
TargetBeta
IGSF8 →read by rule
“A human, Fc-attenuated immunoglobulin G1 (IgG1) monoclonal antibody targeting the immune checkpoint immunoglobulin superfamily member 8 (IGSF8; PGRL; PG regulatory-like protein, KCT-4, CD81 partner 3; LIR-D1; KASP; KAI/CD82 associated protein; EWI-2; Glu-Trp-Ile EWI motif-containing protein 2), ”NCIt, by rule
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07623642Uterine Cervical Neoplasms · China | 2 | Not yet recruiting | Jun 15, 2028 | 227 |
| NCT07070518Neoplasms · China | 2 | Recruiting | Jul 16, 2027 | 350 |
| NCT05669430Neoplasms · United States | 2 | Recruiting | Dec 15, 2026 | 365 |
How it is read
Names in the registry
- “GV20-0251”, 4 entries
Conditions, from the studies’ own filings
- Neoplasms, 2 studies
- Uterine Cervical Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.